October 22, 2025: More People Join Ozempic Group Litigation in October, As Board Members Resign As of October 2025, there are now 2,809 active lawsuits due to serious side effects of Ozempic and other GLP-1 drugs
The huge demand for these medicines has generated a black market of fake and illegal products across Europe including Ireland

Here are the key recommendations: 1 Type 2 Diabetes with No Relevant Comorbidities First-line therapy: Modified-release Metformin + SGLT2 inhibitor If Metformin is contraindicated or not tolerated: SGLT2 inhibitor monotherapy 2 Type 2 Diabetes with Heart Failure Initial therapy: Modified-release Metformin + SGLT2 inhibitor If Metformin cannot be used: SGLT2 inhibitor alone 3 Type 2 Diabetes with Atherosclerotic Cardiovascular Disease (ASCVD) Recommended combination therapy: Metformin SGLT2 inhibitor Semaglutide (up to 1 mg weekly) If Metformin is contraindicated: SGLT2 inhibitor + Semaglutide 4 Early-Onset Type 2 Diabetes Initial treatment: Modified-release Metformin + SGLT2 inhibitor Consider adding: GLP-1 receptor agonist or Tirzepatide for improved glycemic and cardiometabolic outcomes 5 Type 2 Diabetes with Obesity Recommended first-line therapy: Modified-release Metformin + SGLT2 inhibitor Additional weight-focused therapies may be considered based on individual patient needs

Additionally, systemic side effects associated with sustained growth hormone stimulation include symptoms such as abnormal tissue growth, joint discomfort, and potential enlargement of the heart (cardiomegaly), Roberts says (21)
If the findings translate to human users, they raise concerns that Ozempic side effects may not only result in cardiovascular muscle loss, but could also lead to an intolerance for exercise, which could have other long-term detrimental health effects
Canadian researchers can review both retatrutide and tesamorelin product options through Great Northern Peptides, including individual product pages for each compound